Stock Ratings / Health Care / TNXP / earnings

PLYX (31) NTHI (33) RTSN (48) COYA (35) ⌘ Pro Terminal →

Tonix Pharmaceuticals Holding Corp. (TNXP) Next Earnings Date & Expected ±12.5% Move

Q: Where is TNXP trading relative to its 50-day, 200-day, and 52-week technical levels?

TNXP last traded at $5.10 (-3.41% on volume of 567,234 shares), positioning the stock -45.69% below its 50-day simple moving average ($9.39) and -58.94% below its 200-day simple moving average ($12.42). Across its 52-week range of $4.96 to $20.56, TNXP sits at the 0.9% percentile with a 14-day RSI of 17.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.46 to $5.74).

Q: When is TNXP's next earnings date?

Based on SEC filing cadence, Tonix Pharmaceuticals Holding Corp. (TNXP)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is TNXP stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for TNXP, spanning a range between $4.46 and $5.74.

$5.10 -3.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.06

Tonix Pharmaceuticals Holding Corp. (TNXP) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $90.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TNXP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TNXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $5.10 (-3.41% 1D, market cap $90.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNXP ranks #904 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TNXP compare to PLYX and NTHI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNXP carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 49.3%, and ROIC of -35.0%. By comparison, PLYX (Polaryx Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, TNXP leads on earnings multiple (N/A) while TNXP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TNXP?

▼

Per TNXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001430306), Tonix Pharmaceuticals Holding Corp. generated $13.1M in revenue (+29.8% YoY), -$124.0M in net income, and -$103.2M in free cash flow against $277.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.06 (-0.80%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNXP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY TNXP SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 17.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.64-13.7% Next Q

Q2 (-2Q)

Grade E$5.73-7.5% Next Q

Q3 (-1Q)

Grade E$5.30-3.8% Next Q

Current

Grade E$5.10-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TNXP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TNXP currently carries a cautious 28/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.39) and Max Pain ($5.35) forces dealer call-delta covering toward $21.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNXP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TNXP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.64 Expected Swing

MODEL EARNINGS SETUP GAUGE

TNXP Quantitative Pre-Earnings Setup: 28/100

Trailing EPS: $4.25 • YoY Revenue Growth: 29.8%

Model Bullish Setup (28/100)Model Risk Weight (72/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$13.1M	-$124.0M	-$103.2M	49.3%
FY 2024	2024-12-31	$10.1M	-$130.0M	-$61.0M	23.1%
FY 2023	2023-12-31	$7.8M	-$116.7M	-$102.0M	49.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNXP)

✓Walkthrough of TNXP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TNXP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.86%▼ SUPPORT BREAKDOWN

2026-11-02O $5.10H $5.22L $5.10C $5.10VOL 18.0K

RES: $13.66SUP: $5.59SMA50: $9.39SMA200: $12.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNXP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNXP Butterfly Map → + Track TNXP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +29.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TNXP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNXP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TNXP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNXP)

Health Care Rank #904 of 1016 ⚔️ PLYX vs TNXP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNXP vs. PLYX, NTHI, RTSN, COYA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tonix Pharmaceuticals Holding Corp. (TNXP) ranks #904 by composite RQD confidence (28/100, grade E) and #676 by equity capitalization ($90.6M). Within this direct 5-issuer industry benchmark cohort, TNXP leads on earnings valuation at N/A trailing P/E, while TNXP leads on capital efficiency and profitability with -35.0% ROIC and 49.3% gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with TNXP at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TNXP ACTIVE Tonix Pharmaceuticals Holding Corp.	E	28/100	—	49.3%	-35.0%	-3.41%	$90.6M	Benchmark Subject
PLYX Polaryx Therapeutics Inc.	E	31/100	—	—	-35.0%	-5.91%	$92.7M	/plyx-vs-tnxp →
NTHI NeOnc Technologies Holdings Inc.	E	33/100	—	—	-35.0%	+4.49%	$92.9M	/nthi-vs-tnxp →
RTSN Retension Pharmaceuticals Inc.	D	48/100	—	—	—	-3.97%	$93.2M	/rtsn-vs-tnxp →
COYA Coya Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.30%	$93.4M	/coya-vs-tnxp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001430306

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tonix Pharmaceuticals Holding Corp. (TNXP) reported GAAP revenue of $13.1M (+29.8% vs. FY2024 revenue of $10.1M , and +68.7% cumulative change since FY2023) , GAAP net income of -$124.0M, operating cash flow of -$99.8M, and free cash flow of -$103.2M (-69.1% YoY). On the balance sheet, TNXP closed FY2025 with $277.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.1M	-$124.0M	-$99.8M	-$103.2M	$277.2M	—
FY2024 (FY)	2024-12-31	$10.1M	-$130.0M	-$60.9M	-$61.0M	$162.9M	$4.7M
FY2023 (FY)	2023-12-31	$7.8M	-$116.7M	-$102.0M	-$102.0M	—	—

3. TNXP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TNXP compare to PLYX and NTHI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TNXP?

Where is TNXP trading relative to its 50-day, 200-day, and 52-week technical levels?

TNXP last traded at $5.10 (-3.41% on volume of 567,234 shares), positioning the stock -45.69% below its 50-day simple moving average ($9.39) and -58.94% below its 200-day simple moving average ($12.42). Across its 52-week range of $4.96 to $20.56, TNXP sits at the 0.9% percentile with a 14-day RSI of 17.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.46 to $5.74).

TNXP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is TNXP's next earnings date?

Based on SEC filing cadence, Tonix Pharmaceuticals Holding Corp. (TNXP)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is TNXP stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for TNXP, spanning a range between $4.46 and $5.74.

Direct Sub-Reports: TNXP RQD Cockpit TNXP 12M Forecast TNXP Earnings & Move TNXP Dividends & DRIP TNXP Insiders & 13F TNXP Whale Options TNXP Profit Sankey TNXP News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TNXP — Tonix Pharmaceuticals Holding Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:31Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TNXP scores 28 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 2 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. This is the weakest pillar and the main driver of the low score: the company is not currently generating cash returns on invested capital.
Whale 13F Flow: 5 / 20. The RQD rating describes institutional accumulation and options positioning as weak in this framework. Holder-level detail is not available in source data (see Analyst View below).
Insider Conviction: 5 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low. No individual insider transactions are provided in the source data.
Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 and the score reflects sector sensitivity. Beta of 1.0 means the stock is modeled to move in line with the broad market, which offers no defensive cushion.
Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 0.2, Piotroski F is 5/9, and Debt/Equity is 0.5. An Altman Z well below conventional distress thresholds is the most serious forensic flag in the data.

Investor implications: the upside case rests almost entirely on a future turn in the cash engine, which the current data does not show. The valuation tradeoff is that a $90.6M market cap is being paid for a company with negative operating and net margins and an operating loss of $-125.7M in FY 2025 against revenue of $13.1M. Balance-sheet fragility (low Altman Z) raises the risk of dilution or financing stress, which the source data does not resolve. The RQD framework therefore treats the stock as a forensic-risk name rather than a value or growth candidate on the evidence provided.

Business

Tonix Pharmaceuticals Holding Corp. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations, per the company profile. The profile does not describe specific products, customers, or revenue streams. Per the SEC financials, the company reported revenue of $13.1M for FY 2025 and $10.1M for FY 2024, indicating a revenue base that is small relative to its reported operating losses. How the company monetizes its products is not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$13.1M	$-125.7M	$-124.0M	N/A	$-103.2M	$207.6M	N/A
FY 2024	$10.1M	$-136.7M	$-130.0M	N/A	$-61.0M	$98.8M	$4.7M
FY 2023	$7.8M	$-118.4M	$-116.7M	N/A	$-102.0M	N/A	N/A

Per the market data, gross margin is 49.3%, while operating and net margins are both -60%. ROIC is -35%, and the RQD rating cites an Altman Z of 0.2 and a Piotroski F of 5/9. Reported cash rose to $207.6M in FY 2025 from $98.8M in FY 2024, though free cash flow remained deeply negative at $-103.2M, and the RQD rating cites a Debt/Equity of 0.5. Whether this cash position is sufficient to fund continued losses is not resolved in source data.

Recent Catalysts & News Wire Analysis

The news feed contains six items, all tagged to TNXP, from aggregators including StockInvest.us, TradingView, Moomoo, Simply Wall St, MarketBeat, and Stock Titan. Most are generic market-coverage pieces flagged YELLOW.

Rating action: A MarketBeat item (flagged GREEN, CATALYST) reports that the stock rating was raised to "Hold" at Wall Street Zen. This is the only item tagged as a catalyst.
Clinical/medical catalyst: A Stock Titan item (YELLOW, MARKET WIRE) states that Tonix will present an analysis of its treatment relating to fibromyalgia, which it describes as affecting more than 10 million U.S. adults. The presentation's timing, data, and outcome are not available in source data.
Market-coverage items: Remaining headlines cover price forecasts, options chains, and analyst predictions without specific new fundamental information.

Risk watch items: the news feed contains no earnings-date, financing, or dilution disclosures. The butterfly graph contains no proprietary signals (see below).

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply_chain is "NONE," with no butterfly links and no proprietary signals. Upstream supplier, downstream customer, and sector-correlation relationships are therefore not available in source data. Investors should watch for any manufacturing, licensing, or distribution partner disclosures, as well as sensitivity to the broader Health Care sector, but the source data does not quantify these.

Open Questions

What are the company's specific products, revenue sources, and customer concentration, given that revenue is $13.1M against a $-125.7M operating loss?
Is the $207.6M reported cash balance sufficient to cover FY 2025's $-103.2M free cash flow burn, and what is the financing or dilution plan?
What is the outcome, data, and timing of the fibromyalgia treatment analysis referenced in the news feed?
What is the company's debt structure, given debt of $4.7M in FY 2024 and an FY 2025 debt figure marked N/A?
Why are P/E, EV/EBITDA, and EPS unavailable, and what would they show given reported net losses?

TNXP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tonix Pharmaceuticals Holding Corp. (TNXP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TNXP Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 2h ago

Tonix Pharmaceuticals Stock Price Forecast. Should You Buy TNXP?

StockInvest.us report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 5h ago

Tonix Pharmaceuticals Holding Corp. Estimates – NASDAQ:TNXP

TradingView report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 8h ago

Tonix Pharmaceuticals(TNXP) Stock Options Chain | Quotes & News

Moomoo report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 11h ago

Tonix Pharmaceuticals Holding (NasdaqGS:TNXP) Stock Forecast & Analyst Predictions

Simply Wall St report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 14h ago

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Raised to "Hold" at Wall Street Zen

MarketBeat report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 17h ago

More than 10 million U.S. adults have fibromyalgia. Tonix will present an analysis of its treatment.

Stock Titan report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 20h ago

The Technical Signals Behind (TNXP) That Institutions Follow

Stock Traders Daily report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 23h ago

Companies Like Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Could Be Quite Risky

Simply Wall St report covering Tonix Pharmaceuticals Holding Corp. (TNXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TNXP Bull vs. Bear Conversation Board — What's Your Call at $5.10?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TNXP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.65 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TNXP (E • RQD 28/100) a Buy at $5.28?

Welcome to the TNXP (Tonix Pharmaceuticals Holding Corp.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.33 (-18.0%)

Spot @ $5.28

Pump the brakes on TNXP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TNXP, but look at what you are paying: current EV/EBITDA multiples with 49.3% gross margins. Unless Tonix Pharmaceuticals Holding Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.65 (+25.9%)

Spot @ $5.28

TNXP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TNXP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $5.28 (52-wk range $4.93 - $6.09), any beat on forward guidance forces shorts and underweight funds to chase.